Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?

The Lancet Respiratory Medicine

Volumn 8, Issue 5, 2020, Pages 436-438

  Halpin, David M G ^a   Faner, Rosa ^b   Sibila, Oriol ^b   Badia, Joan Ramon ^b   Agusti, Alvar ^b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CICLESONIDE; CORTICOSTEROID; CYTOKINE; OXYGEN;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COMORBIDITY; CORONAVIRUS DISEASE 2019; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE SEVERITY; GLOBAL DISEASE BURDEN; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MEDICAL DECISION MAKING; MORTALITY; NOTE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS REPLICATION; BETACORONAVIRUS; CHRONIC DISEASE; COMPLICATION; CORONAVIRUS INFECTION; PANDEMIC; RESPIRATORY TRACT DISEASE; VIRUS PNEUMONIA;

BETACORONAVIRUS; CHRONIC DISEASE; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL; RESPIRATORY TRACT DISEASES;

EID: 85083222260     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(20)30167-3     Document Type: Note

References (11)

1. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
2. Yin, Y, Wunderink, RG, MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 23 (2018), 130–137.
3. Onder, G, Rezza, G, Brusaferro, S, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA, 2020 published online March 23. DOI:10.1001/jama.2020.4683.
4. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6913e2-H.pdf, 2020. (Accessed 2 April 2020)
5. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly 2 (2020), 113–122.
6. Liu, Y, Liu, G, Wu, H, Jian, W, Wild, SH, Gasevic, D, Sex differences in non-communicable disease prevalence in China: a cross-sectional analysis of the China Health and Retirement Longitudinal Study in 2011. BMJ Open, 7, 2017, e017450.
7. Su, N, Lin, J, Chen, P, et al. Evaluation of asthma control and patient's perception of asthma: findings and analysis of a nationwide questionnaire-based survey in China. J Asthma 50 (2013), 861–870.
8. Yamaya, M, Nishimura, H, Deng, X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig, 2020 published online Feb 21. DOI:10.1016/j.resinv.2019.12.005.
9. Matsuyama, S, Kawase, M, Nao, N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv, 2020 published online March 12. DOI: 10.1101/2020.03.11.987016 (preprint).
10. Iwabuchi, K, Yoshie, K, Kurakami, Y, Takahashi, K, Kato, Y, Morishima, T, COVID-19. Three cases improved with inhaled ciclesonide in the early to middle stages of pneumonia. http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_200310.pdf, 2020 (in Japanese). (Accessed 27 March 2020)
11. Stockman, LJ, Bellamy, R, Garner, P, SARS: systematic review of treatment effects. PLoS Med, 3, 2006, e343.